Interleukin-3

• Take 15 minutes before meals.

DIRECTIONS Take 15 minutes before meals Adults and children 12 years and older 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children between 12 years and 6 years of age 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children under 6 years 5 drops twice a day in a glass of water.

Stop use and ask doctor if symptoms worsen or persist more than 3 days.

1. 1Off Label Use5315%
2. 2Pyrexia349.5%
3. 3Hypotension329.0%
4. 4Fatigue236.4%
5. 5Nausea236.4%
6. 6Cardiotoxicity226.2%
7. 7Chills226.2%
8. 8Decreased Appetite195.3%
9. 9Diarrhoea195.3%
10. 10Malignant Neoplasm Progression195.3%
11. 11Anaemia174.8%
12. 12Disease Progression174.8%
13. 13Product Use In Unapproved Indication154.2%
14. 14Vomiting154.2%
15. 15Death143.9%

Recent PubMed references pinned to Interleukin-3 as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Context-Dependent Regulation of Microglial Metabolic and Immune States via IL-3/CD123 Signaling: Implications for Glial Crosstalk and Cognitive Impairment.
  Molecular neurobiology · 2026 · Yu Z, Lin Y, Yang E, et al.
  PMID 42026226DOI 10.1007/s12035-026-05815-x
• IL-3 Modulates Microglia Polarization and Attenuates Neuroinflammation in Traumatic Brain Injury.
  Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · Huang N, Zhang Q, Chen Y, et al.
  PMID 41915872DOI 10.1002/advs.202504511
• Fibrosis-memory is mediated by IL-3-producing T cells and drives progression of fibrosis.
  The Journal of clinical investigation · 2026 · Buchtler S, Frühauf A, Neumayer S, et al.
  PMID 41837289DOI 10.1172/JCI192095
• Astrocyte-microglia IL-3-IL-3Rα signaling drives JAK2/STAT5-dependent neuroinflammation and neurodegeneration after status epilepticus.
  Experimental brain research · 2026 · Xie L, Liu L, Wang X, et al.
  PMID 41801405DOI 10.1007/s00221-026-07260-7
• A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm.
  International journal of hematology · 2026 · Yokota A, Munakata W, Kiguchi T, et al.
  PMID 41493719DOI 10.1007/s12185-025-04151-5
• IL-33 and IL-3 synergistically induce CD25 expression on human basophils without functional IL-2 signaling: a potential marker of severe COVID-19.
  Frontiers in immunology · 2025 · Retnakumar SV, Singh SC, Chauvin C, et al.
  PMID 41459501DOI 10.3389/fimmu.2025.1718240
• Deciphering the structural and functional impact of interleukin-3 (IL-3) variants: Insights from site-directed mutagenesis, computational modeling, molecular dynamics simulations, and implications for anticancer therapies and immune regulation.
  Mutation research · 2026 · Yaseen AR, Nisar U, Ahmad M, et al.
  PMID 41418394DOI 10.1016/j.mrfmmm.2025.111927
• Priming of mouse pre-osteoblasts with Interleukin-3 attenuates TNF-α-induced-inhibition of osteoblast differentiation.
  BMC musculoskeletal disorders · 2025 · Piprode V, Behera S, Karhade J, et al.
  PMID 40624526DOI 10.1186/s12891-025-08610-2

The 10 most recently updated of 14 ClinicalTrials.gov registrations naming Interleukin-3 as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
  Recruiting · Phase 2 · Interventional · 40 enrolled · M.D. Anderson Cancer Center
  NCT04216524updated 2026-04-14
• Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
  Active not recruiting · Phase 1 · Phase 2 · Interventional · 64 enrolled · M.D. Anderson Cancer Center
  NCT05038592updated 2026-04-14
• Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
  Recruiting · Phase 1 · Interventional · 43 enrolled · City of Hope Medical Center
  NCT06498973updated 2026-03-05
• Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
  Terminated · Phase 1 · Phase 2 · Interventional · 4 enrolled · M.D. Anderson Cancer Center
  NCT05032183updated 2025-08-11
• Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
  Terminated · Phase 2 · Interventional · 3 enrolled · M.D. Anderson Cancer Center
  NCT04317781updated 2024-07-31
• Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
  Withdrawn · Phase 1 · Interventional · 0 enrolled · Jonsson Comprehensive Cancer Center
  NCT05720988updated 2024-03-08
• AOA in Recurrent Fertilization Failure
  Completed · Phase 4 · Interventional · 150 enrolled · MOHAMED BEHERY
  NCT04744753updated 2021-02-09
• DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
  Completed · Phase 1 · Phase 2 · Interventional · 11 enrolled · University of Texas Southwestern Medical Center
  NCT00397579updated 2019-04-23
• Inflammatory Cytokines Associated With Perinatal Brain Injury
  Completed · Observational · 1,067 enrolled · NICHD Neonatal Research Network
  NCT01035697updated 2019-03-22
• A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
  Completed · Phase 1 · Interventional · 30 enrolled · CSL Limited
  NCT01632852updated 2015-10-09

Frequently asked questions

What is Interleukin-3 used for?

According to FDA labeling, Interleukin-3 carries indications including: Take 15 minutes before meals.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.